Jounce Therapeutics Inc (NASDAQ:JNCE) saw a large growth in short interest during the month of November. As of November 29th, there was short interest totalling 851,400 shares, a growth of 88.6% from the November 14th total of 451,400 shares. Currently, 5.4% of the shares of the stock are short sold. Based on an average trading volume of 431,700 shares, the short-interest ratio is presently 2.0 days.
Shares of NASDAQ:JNCE opened at $9.14 on Thursday. The firm has a market cap of $270.15 million, a P/E ratio of 3.61 and a beta of 3.75. The company has a quick ratio of 13.60, a current ratio of 13.60 and a debt-to-equity ratio of 0.09. Jounce Therapeutics has a 12-month low of $2.66 and a 12-month high of $9.80. The business has a fifty day simple moving average of $5.13 and a 200 day simple moving average of $4.34.
Jounce Therapeutics (NASDAQ:JNCE) last announced its earnings results on Thursday, November 7th. The company reported $2.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.66. The business had revenue of $119.45 million during the quarter, compared to analyst estimates of $99.97 million. Jounce Therapeutics had a return on equity of 64.54% and a net margin of 46.11%. As a group, equities research analysts expect that Jounce Therapeutics will post 1.92 EPS for the current year.
A number of large investors have recently made changes to their positions in JNCE. Vanguard Group Inc. raised its position in Jounce Therapeutics by 30.8% during the 2nd quarter. Vanguard Group Inc. now owns 800,150 shares of the company’s stock worth $3,961,000 after purchasing an additional 188,540 shares during the last quarter. Millennium Management LLC bought a new position in shares of Jounce Therapeutics in the 3rd quarter worth about $528,000. Essex Investment Management Co. LLC bought a new position in shares of Jounce Therapeutics in the 3rd quarter worth about $360,000. Strs Ohio bought a new position in shares of Jounce Therapeutics in the 2nd quarter worth about $470,000. Finally, Acadian Asset Management LLC raised its position in shares of Jounce Therapeutics by 29.0% in the 2nd quarter. Acadian Asset Management LLC now owns 376,090 shares of the company’s stock worth $1,862,000 after acquiring an additional 84,557 shares in the last quarter. 70.58% of the stock is owned by institutional investors and hedge funds.
JNCE has been the subject of a number of research reports. ValuEngine upgraded Jounce Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday. Cowen reiterated a “hold” rating on shares of Jounce Therapeutics in a research note on Tuesday, November 12th. BidaskClub upgraded Jounce Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Zacks Investment Research raised Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $4.50 target price for the company in a research report on Saturday, November 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the stock. Jounce Therapeutics presently has an average rating of “Hold” and a consensus price target of $4.50.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.
Featured Article: What is the Beige Book?
Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.